People with neuromyelitis optica spectrum disorder (NMOSD) who test positive for self-reactive antibodies against the aquaporin 4 (AQP4) protein…
Articles by Margarida Maia, PhD
A predictive model based on laboratory and clinical risk factors for relapses in neuromyelitis optica spectrum disorder (NMOSD) was…
People with neuromyelitis optica spectrum disorder (NMOSD) have significantly higher levels of the signaling molecule CXCL13 in their blood…
BAT4406F, an experimental treatment in the pipeline of Bio-Thera Solutions, reduced the number of circulating immune B-cells that produce…
Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and…
A seaweed-derived preparation named GV-971 (sodium oligomannate) that has anti-inflammatory effects through the gut-brain axis, delayed the onset and progression…
HNSA-5487, Hansa Biopharma’s experimental treatment for neuromyelitis optica spectrum disorder (NMOSD) and other autoimmune diseases, safely and effectively…
Combining blood-cleaning therapies such as plasma exchange or immunoadsorption with standard steroid treatment can improve recovery outcomes in patients having…
People having area postrema syndrome (APS), that is, uncontrollable nausea, vomiting, or hiccups, as the first symptom of neuromyelitis…
People with neuromyelitis optica spectrum disorder (NMOSD) have significantly lower vitamin D levels in their blood than do healthy…